Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia - Related Studies

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

This study has been completed.

Study NCT00081133. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia

2	Additional conditions recognized in this trial
		Blast Crisis
		Leukemia, Lymphoid
		Leukemia, Myelogenous, Chronic, BCR-ABL Positive
		Leukemia, Myeloid
		Precursor Cell Lymphoblastic Leukemia-Lymphoma

3	More general conditions related to this trial
		Bone Marrow Diseases
		Cell Transformation, Neoplastic
		Hematologic Diseases
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Myeloproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Neoplastic Processes
		Pathologic Processes

4	Interventions listed in this trial
		arsenic trioxide
		imatinib mesylate

5	Additional drug interventions recognized in this trial
		Imatinib

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Kinase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Memorial Sloan-Kettering Cancer Center
		National Cancer Institute (NCI)